J Am Coll Cardiol August 2023 PMID 37495284

First-in-Human Experience With Impella 5.0/5.5 for High-Risk Patients With Advanced Heart Failure Undergoing VT Ablation.

Jakub Sroubek, Ramya Vajapey, Joseph J Sipko, Edward G Soltesz, Aaron J Weiss, Mandeep Bhargava, Ayman A Hussein, Mohamed Kanj, Walid I Saliba, Tyler L Taigen, Oussama M Wazni, Pasquale Santangeli

Full text PDF Download social card

Mentions

Peak: 24 in Jul 2023

across 4 sources since May 2023

Extended reach

89,542

potential audience

Total likes

231

Video views

426

Mentions per month

May 2023 – Mar 2024

Where it's discussed

X / Twitter42 posts
News3 articles
YouTube2 videos
Facebook2 posts

AI synopsis

What people are saying

The discussions reflect a generally positive and interested attitude, with some posters expressing excitement about the publication with statements like 'Excited to see our research' and retweets recognizing the significance of the milestone. The tone and choice of words indicate a respectful appreciation of the research's novelty, though the overall perceived impact remains cautious and optimistic rather than transformative.

AgreementModerate agreement

Most discussions show support or neutral acknowledgment of the publication, as seen in comments like 'Excited to see our research...' and reposts endorsing the study, indicating a general consensus of interest and validation.

InterestHigh interest

Posts express high engagement and curiosity about the research, demonstrated by words like 'Excited' and mentions of sharing and reposting the publication widely.

EngagementModerate engagement

Several posts include references to the implications of the research, with some highlighting their own involvement or enthusiasm, such as 'Our research' and sharing official journal links.

ImpactModerate impact

While there is recognition of the study’s significance, the discussions predominantly acknowledge its importance without asserting it will revolutionize practice yet, reflected in phrases like 'First-in-Human' and expressions of interest rather than defin

Abstract in brief

This text discusses the first-ever use of the Impella 5055 device in humans to assist high-risk patients with advanced heart failure who are undergoing ventricular tachycardia (VT) ablation, a procedure to treat abnormal heart rhythms.
It highlights the significance of this medical experience as a milestone in using the Impella 5055 for complex heart procedures, potentially improving patient outcomes.
The report suggests that the Impella 5055 may offer a new support option for high-risk heart failure patients undergoing high-stakes procedures like VT ablation.]

Read the full abstract

All mentions

First-in-Human Use of Impella 5.0/5.5 for High-Risk Heart Failure Patients

This video covers the first use of the Impella 5055 device in humans to support high-risk patients with advanced heart failure undergoing VT ablation, highlighting a milestone that could improve outcomes in complex…

Heart Rhythm TV · Nov 10, 2023 407 views

Early Anticoagulation Benefits in Atrial Fibrillation Stroke Patients

This week's podcast discusses the timing of direct oral anticoagulant initiation in atrial fibrillation patients post-acute ischemic stroke. The study reveals that early treatment is linked to a reduced incidence of…

Medscape · Mar 27, 2024 20 views

Mahek Shah, MD

@Cardiobro · X

High risk CABG will go the same way https://t.co/Z89gLMLIWh

Nov 5, 2023 · 4 likes · 1,828 followers View post →

Fırat Özcan

@drfiratozcan · X